SBC Medical Group Holdings (SBC) Cash & Equivalents (2022 - 2025)

SBC Medical Group Holdings has reported Cash & Equivalents for 4 years, with the latest figure at $163.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 30.97% year-over-year to $163.8 million; the trailing twelve-month figure through Dec 2025 stood at $163.8 million (up 30.97% YoY), and the FY2025 full-year result was $163.8 million, up 30.97% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $163.8 million, up from $127.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $163.8 million in Q4 2025, with the low at $217348.0 in Q1 2023.
• Historically, Cash & Equivalents has averaged $78.8 million across 4 years, with a median of $114.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 23822.07% — and 2025, when it decreased 7.25%.
• SBC Medical Group Holdings' Cash & Equivalents stood at $485564.0 in 2022, then surged by 21117.17% to $103.0 million in 2023, then advanced by 21.38% to $125.0 million in 2024, then jumped by 30.97% to $163.8 million in 2025.
• The last three Cash & Equivalents figures came in at $163.8 million (Q4 2025), $127.4 million (Q3 2025), and $152.7 million (Q2 2025), per Business Quant data.